Monday, June 29, 2020 12:58:14 PM
Source: PR Newswire (Canada)
IPA Announces Discovery of Functional Antibodies from Humans and Llama (VHH), Identified Using IPA Phage Display Technology
VICTORIA, BC, June 29, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), an experienced leader in full-service, therapeutic antibody discovery and development, today announced the identification of numerous lead candidate antibodies with highly-potent neutralizing activity in vitro, which are being manufactured for further testing and possible inclusion in the Company's PolyTopeTM mAb Therapy to combat the COVID-19 pandemic.
ImmunoPrecise Antibodies Ltd. Logo (CNW Group/ImmunoPrecise Antibodies Ltd.)
On March 12th, 2020, ImmunoPrecise announced several preclinical programs currently being undertaken to assist in the efforts against SARS-CoV-2. Today's announcement updates the Company's progress on the development of a PolyTope™ mAb therapy designed to treat severely ill patients, as well as protect high-risk individuals such as those exposed to the virus, front-line workers, the elderly, and the immunocompromised.
ImmunoPrecise deployed several proprietary discovery platforms that leveraged the immune systems of humans, llama, rabbits and Ligand Pharmaceutical's (NASDAQ:LGND) OmniAbÒ genetically engineered rats producing human antibodies. The neutralizing antibodies announced today are the result of functional screenings from the top 300 lead antibodies analyzed from the human and llama campaigns. The Company has stated that functional analysis of the remaining 1,300 lead antibodies from the rabbit and OmniAbÒ rat campaigns were performed independently, and they anticipate the release of the preliminary functional data screens from these additional programs in the near future.
"Arriving at this critical point in our preliminary research with many lead, functional therapeutic candidates is indicative of the broad scientific scope of IPA's anti-COVID-19 programs," stated Dr. Jennifer Bath, CEO and President of IPA. "An effective cocktail therapy for COVID-19, targeting multiple epitopes on the virus, could prove fundamental in combating this pandemic in an effective and enduring way."
The Company's scientific approach has led to a diverse set of lead antibody candidates, and thus far has generated many potently neutralizing antibodies to multiple epitopes, supporting the Company's aim of generating a therapeutic that retains efficacy, even as SARS-CoV-2 continues to evolve. To further support the Company's robust scientific approach, IPA is preparing to test these lead antibodies against additional, documented, mutated strains of the virus.
The Company anticipates pre-clinical studies will begin summer 2020.
Jennifer Bath, Ph.D., Chief Executive Officer of ImmunoPrecise, has reviewed and approved the scientific disclosure of this news release.
The use of therapeutics for humans in clinical trials will require approval of the applicable government regulation agency, e.g. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or SARS-CoV-2) at this time.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, ImmunoPrecise may not be successful in the development of any vaccine, therapy or diagnostic kits to be used in the prevention, treatment or diagnosis of SARS-CoV-2, actual revenues and earnings for IPA being lower than anticipated, potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions and disruption of the global economy, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the previous quarter ended January 31, 2020 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies
Recent IPA News
- InterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IA • Business Wire • 03/28/2024 06:35:00 PM
- InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications • Business Wire • 03/28/2024 11:02:00 AM
- IPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IA • Business Wire • 03/20/2024 05:52:00 PM
- IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments • Business Wire • 03/20/2024 11:02:00 AM
- IPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024* • Business Wire • 03/14/2024 11:39:00 PM
- IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* • Business Wire • 03/14/2024 12:05:00 PM
- BioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFT • Business Wire • 03/07/2024 08:24:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 04:19:01 PM
- IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology • Business Wire • 03/07/2024 12:02:00 PM
- L'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024 • Business Wire • 03/04/2024 09:50:00 PM
- IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024 • Business Wire • 03/04/2024 01:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/23/2024 10:29:18 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/23/2024 10:26:04 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 02/15/2024 08:12:47 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 06:53:08 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/10/2024 06:33:21 PM
- IPA présente ses résultats financiers et les récents points forts de son activité pour le deuxième trimestre de l’exercice 2024* • Business Wire • 12/14/2023 08:08:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 01:48:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 01:38:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 01:03:16 PM
- IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024* • Business Wire • 12/14/2023 01:01:00 PM
- IPA annonce la clôture d'une offre publique d'actions ordinaires pour un montant de 1 265 million de dollars • Business Wire • 12/09/2023 02:57:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/08/2023 10:11:10 PM
- IPA Announces Closing of $1.265 Million Public Offering of Common Shares • Business Wire • 12/08/2023 10:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/07/2023 09:53:47 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM